Search hospitals > Hawaii > Honolulu
Queen's Cancer Center - Kuakini
Claim this profileHonolulu, Hawaii 96813
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
222 reported clinical trials
14 medical researchers
Summary
Queen's Cancer Center - Kuakini is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Queen's Cancer Center - Kuakini is involved with conducting 222 clinical trials across 340 conditions. There are 14 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Michael Carney, MD, Jared D. Acoba, and Jami A. Fukui.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Jeffrey L. BerenbergStraub Clinic and Hospital7 years of reported clinical research
Expert in Lung Cancer
Expert in Cancer
28 reported clinical trials
75 drugs studied
Michael Carney, MDKapiolani Medical Center for Women and Children4 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
14 reported clinical trials
29 drugs studied
Jared D. AcobaQueen's Medical Center4 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
15 reported clinical trials
35 drugs studied
Jami A. FukuiKapiolani Medical Center for Women and Children4 years of reported clinical research
Studies Breast Cancer
Studies Cancer
12 reported clinical trials
32 drugs studied
Clinical Trials running at Queen's Cancer Center - Kuakini
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Diffuse Large B-Cell Lymphoma
Laryngeal Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Ovarian Cancer
Colorectal Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Queen's Cancer Center - Kuakini?
Queen's Cancer Center - Kuakini is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Queen's Cancer Center - Kuakini is involved with conducting 222 clinical trials across 340 conditions. There are 14 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Michael Carney, MD, Jared D. Acoba, and Jami A. Fukui.